Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2010

View Archived Issues

Preclinical and early clinical data reported on BC-3781

Extended proof-of-concept and drug interaction studies complete for IDX-899

Eisai details in vitro and in vivo activity of new antifungal E-1210

Researchers claim new glucokinase activators

SEPS Pharma presents new fluconazole prodrugs for fungal infections

Stemsynergy Therapeutics claims new Wnt signaling inhibitors

Deakin University presents new antibacterial agents

CH-14.18 shows promise in phase III trial in neuroblastoma

MV-062926 is active in mouse model of COPD

FDA accepts Accera's IND application for phase II/III AC-1204 trial in AD

NCI and Lixte Biotechnology collaborate on anticancer agent LB-100

ISTO Technologies' phase I trial of NuQu in discogenic back pain fully enrolled

NeuroSearch patents new voltage-gated K(V)7 potassium channel modulators

Roche buys rights to hepatitis C therapy danoprevir from InterMune

Sirius Genomics receives NRC-IRAP funding for discovery of genomic biomarkers

NIH funds Profectus BioSciences to develop HIV vaccine

Bepotastine besilate nasal spray is efficacious in allergic rhinitis

Sucampo submits marketing application for Amitiza in Japan

Xeomin launched in U.S. for cervical dystonia and blepharospasm

Pfizer acquires FoldRx Pharmaceuticals

FDA agrees to SPA for phase III Estybon trial in myelodysplastic syndromes

Recruitment complete in phase II tideglusib trial in progressive supranuclear palsy

DynPort Vaccine begins phase IIb trial of recombinant plague vaccine

ChemGenex completes pre-NDA meeting with FDA for Omapro

Neoprobe completes Lymphoseek pre-NDA meeting

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...